Approved for cancer treatment 30, IFNα can enhance nature killer (NK) cell peripheral maturation in the spleen and increase its cytolytic activity toward tumors 31, 32, consistent with the observed increases in recruitment of immune cells in our xenograft experiments. The gene discussed is IFNA2; the disease is cancer.